Deals

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full
BioArcticNovartis

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full

BioArctic AB (OTCMKTS: BRCTF) announced that Novartis AG (NYSE: NVS) has notified the company of its decision to terminate the Option, Collaboration and License Agreement entered into in August 2025.…

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry's Largest Deal of Its Kind

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry’s Largest Deal of Its Kind

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
AIBrii Biosciences

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
GlaxoSmithKlineGSK

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
B&K CorporationHKG: 2396

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
GSKOxford BioTherapeutics

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Show More